While I think there is accumulation going on, the downward slide is proving difficult to stop.
The break through $1.30 led to a bit of a quick probe lower, leading to a larger thrust down (red levels on the side).
Apart from the obvious weakness of a lot of stocks in the current bear market, possible reasons include:
Lack of favourable news.
Competitive/regulated nature of pharma market.
Govt proposals to reduce/restrain margins.
Sigma missing out on acquisitions recently and opportunity for consolidation.
Entry of Indian firm ( name escapes me) to Aust market.
In short, there seem to be plenty of reasons not to buy SIP at present and no compelling reason to buy. That said, I don't see it as a company in imminent danger of going out of business, rather as just a steady performer.
Agree I dont think it will go under, with distribution network like SIP someone will buy it out before something happen to it in a worse case scenario.
but generic drugs is a tough game, anyone can make them and the cheaper you make the better you are at taking on your arch rival and there are pressure for SIP as oversea generic makers are coming in to Australia.
I dont think it can go much lower than where it is at a moment I reckon 80 cents is a low as it go... I buy it at 80 cents actually if it hits that low.
Existing Eligible Retail Shareholders took up approximately 32% of their
Entitlements. New Shares not taken up under the Retail Entitlement Offer were sold
through a bookbuild process conducted on 8 October 2009. The Retail Entitlement
Bookbuild priced at the Issue Price of $1.02.
You would think that the existing holders are not very confident, not to take up thier entitlements!
What exactly does this "bookbuild" mean?????
I 'spose it didn't matter as the underwriters took up the remaining shares therefore this bookbuild play. I can understand SIP not reoffering the SPP (like AIO and BLY did) with so a poor take up.Traded under the issue price today...they prob should of discounted the issue further than they did, the 32% take up by holders is pretty weak and a sure sign that the issue was over priced.
I wonder if anyone had an opinion as to why SIP is taking such a hammering.
The analysis on comsec shows an issue with short term liabilities due to retirement of some debt in the short term, yet the half yearly report from the company says they have renegotiated all their debt with west pac through 2011 so both can't be correct or am I missing something.
The average projected dividends for the next two years is at 7.2 cents FF grossed up to 10.286 Cents. At todays price 91.5 cents that is 11.2 odd percent return.
Comsec analysts have it as 2 strong buy and 1 hold .
The only thing I can see that might be wrong is the amount of debt they have but having said that wespac's just redone their loans and they would have been through them with a fine tooth comb.
So my question is before I average down yet again is there something I am missing here. The market seems to hate the stock and the volumes in market depth look crook.
Cheers
Gary
I wonder if anyone had an opinion as to why SIP is taking such a hammering.
The analysis on comsec shows an issue with short term liabilities due to retirement of some debt in the short term, yet the half yearly report from the company says they have renegotiated all their debt with west pac through 2011 so both can't be correct or am I missing something.
The average projected dividends for the next two years is at 7.2 cents FF grossed up to 10.286 Cents. At todays price 91.5 cents that is 11.2 odd percent return.
Comsec analysts have it as 2 strong buy and 1 hold .
The only thing I can see that might be wrong is the amount of debt they have but having said that wespac's just redone their loans and they would have been through them with a fine tooth comb.
So my question is before I average down yet again is there something I am missing here. The market seems to hate the stock and the volumes in market depth look crook.
Cheers
Gary
to me this business is pretty ordinary at best, they don't do anything special and the oversea generic drug maker probably can do it a lot cheaper.
They have no competitive advantage, they are in the business of cheapest price win the game.... and are they the cheapest?
and with this sort of business you need volume because they cant command price, you need to command volume and if volume is not there
so is the bottom line.
I don't own the stock and would never own it either, failed my test
Yes it probably is a pretty ordinary business. Yes overseas drug companies could probably make generics a lot cheaper. But what the overseas companies do not have is distribution. When you walk into an Amcal pharmacy they don't ask you if you'd like the chinese version of this drug. They do ask you if you would like the Australian version of this drug, and they tell you it's cheaper. End off.
I disagree that they have no competitive advantage, they have retail distribution.
I disagree they are in the business of the cheapest, they are in the business of the cheaper. Which they are.
In regard to volume I agree if the volume is not there then there is an issue.
Having said all this all your comments are directed to less than 20% of the companies business. This business is several retail chemist chains who makes a few drugs on the side. You don't seem to be across the business.
What is this test you have that precludes a stock from your portfolio forever. I am constantly evaluating and re evaluating if I had a test that banished a stock to the remainder bin forever it would sure save me a lot of time.
Cheers
Gary
the trading halt is necessary as Sigma expects to make an announcement to the
market in relation to revised earnings guidance arising from year end adjustments
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?